- Home
- JFU vs QTTB Comparison
JFU vs QTTB Comparison
Compare JFU & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFU
- QTTB
- Stock Information
- Founded
- JFU 2006
- QTTB 2015
- Country
- JFU China
- QTTB United States
- Employees
- JFU N/A
- QTTB N/A
- Industry
- JFU Finance: Consumer Services
- QTTB Biotechnology: Pharmaceutical Preparations
- Sector
- JFU Finance
- QTTB Health Care
- Exchange
- JFU Nasdaq
- QTTB Nasdaq
- Market Cap
- JFU 17.1M
- QTTB 18.9M
- IPO Year
- JFU 2019
- QTTB N/A
- Fundamental
- Price
- JFU $1.83
- QTTB $1.97
- Analyst Decision
- JFU
- QTTB Hold
- Analyst Count
- JFU 0
- QTTB 8
- Target Price
- JFU N/A
- QTTB $24.00
- AVG Volume (30 Days)
- JFU 14.0K
- QTTB 226.6K
- Earning Date
- JFU 01-01-0001
- QTTB 08-06-2025
- Dividend Yield
- JFU N/A
- QTTB N/A
- EPS Growth
- JFU N/A
- QTTB N/A
- EPS
- JFU 0.58
- QTTB N/A
- Revenue
- JFU $42,467,427.00
- QTTB N/A
- Revenue This Year
- JFU N/A
- QTTB N/A
- Revenue Next Year
- JFU N/A
- QTTB N/A
- P/E Ratio
- JFU $3.45
- QTTB N/A
- Revenue Growth
- JFU N/A
- QTTB N/A
- 52 Week Low
- JFU $1.01
- QTTB $1.35
- 52 Week High
- JFU $3.60
- QTTB $53.79
- Technical
- Relative Strength Index (RSI)
- JFU 58.35
- QTTB 50.74
- Support Level
- JFU $1.53
- QTTB $1.57
- Resistance Level
- JFU $2.10
- QTTB $2.08
- Average True Range (ATR)
- JFU 0.14
- QTTB 0.22
- MACD
- JFU 0.03
- QTTB -0.03
- Stochastic Oscillator
- JFU 53.45
- QTTB 53.04
About JFU 9F Inc.
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company generates the majority of its revenue from Loan facilitation services. All its revenues are generated from the People's Republic of China.
About QTTB Q32 Bio Inc. Common Stock
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.